Fast Five Quiz: Glycemic Control in Type 2 Diabetes

Romesh Khardori, MD, PhD


February 21, 2023

A sodium-glucose cotransporter 2 (SGLT2) inhibitor with proven benefit for the specific comorbidity is recommended in multiple guidelines, including those from the American Diabetes Association and in Canadian guidelines as part of the glucose-lowering regimen for patients with type 2 diabetes who have established atherosclerotic cardiovascular disease or indicators of high risk, established kidney disease, or heart failure. Multiple clinical trials have demonstrated the beneficial effects of SGLT2 inhibitors, including the EMPEROR-Reduced Clinical trial where empagliflozin was shown to reduce the risk for cardiovascular death by 38% and decline in GFR.

To date, there has been no evidence of similar cardiovascular or renal benefits of lowering glucose using older therapies indicated for patients with type 2 diabetes, such as metformin, sulfonylureas, thiazolidinediones, or insulin, or for the newer dipeptidyl peptidase 4 inhibitors.

Learn more about cardiovascular risk management in type 2 diabetes.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.